Brief: Knight Therapeutics Reports Q1 Results
11/05/2023 12:50
May 11 (Reuters) - Knight Therapeutics Inc GUD.TO :
* KNIGHT THERAPEUTICS REPORTS FIRST QUARTER 2023 RESULTS
* KNIGHT THERAPEUTICS INC Q1 REVENUE ROSE 29 PERCENT TO
C$82,597
* KNIGHT THERAPEUTICS INC - FOR FISCAL 2023, UPDATED
GUIDANCE AND
EXPECTS TO GENERATE $300 TO $320 MILLION IN REVENUE, ON A
NON-GAAP BASIS
* KNIGHT THERAPEUTICS INC - ALL CURRENCIES ARE IN CANADIAN
DOLLARS
Source text for Eikon: ID:nGNXth7T6
Further company coverage: GUD.TO
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Knight Therapeutics
See all newsBrief: Knight Therapeutics Announces Regulatory Approval Of Niktimvo In Brazil
Brief: Knight Therapeutics - Launches Tavalisse In Brazil For Chronic Immune Thrombocytopenia
Brief: Knight Therapeutics Enters Into Exclusive Distribution Agreement With Kyowa Kirin International For Poteligeo® (Mogamulizumab)
Brief: Knight Therapeutics Announces Regulatory Approval Of Tavalisse® In Colombia
Brief: Knight Therapeutics Announces Supplemental Regulatory Submission For Minjuvi In Brazil